Sangart Inc.

Study meets primary endpoint of reducing lactate levels in trauma patients treated with MP4OX

Sangart, Inc. Completes Enrollment in Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients

SAN DIEGO, August 31, 2010 - Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis.

MORE..

Older News

SAN DIEGO, June 30, 2010 - Sangart, Inc., today announced that enrollment was completed in a Phase IIa clinical study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy